Novacea Gains Worldwide Rights To Phase I Cancer Compound From KuDOS
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm announces agreement with AstraZeneca subsidiary to develop and commercialize banoxantrone, for which it already had North American rights.